Saikosaponin D Overcomes Radioresistance in TNBC via MRE11 Delactylation

Study Background and Research Question

Triple-negative breast cancer (TNBC) is a highly aggressive and therapeutically challenging subtype of breast cancer, defined by the absence of estrogen, progesterone, and HER2 receptors. Despite advances in radiotherapy, resistance to treatment remains a primary cause of poor prognosis and high recurrence rates in TNBC. A key feature of many aggressive tumors, including TNBC, is metabolic reprogramming—specifically, a reliance on aerobic glycolysis (the Warburg effect) that results in increased lactate production. Recent evidence indicates that lactate is not simply a metabolic byproduct but also a signaling molecule, capable of driving post-translational modifications such as lysine lactylation, which can modulate DNA repair and contribute to therapy resistance.

The reference study (Li et al., Theranostics 2025) sought to delineate the molecular pathways by which lactate-driven modifications confer radioresistance in TNBC and to identify potential agents that can reverse this resistance by targeting these metabolic-epigenetic interactions.

Key Innovation from the Reference Study

This study provides the first mechanistic evidence that lactate-induced lysine lactylation of the DNA repair protein MRE11 at Lys673 directly enhances DNA repair capacity and radioresistance in TNBC cells. Notably, Saikosaponin D (SSD), a triterpenoid saponin, was found to reverse this effect by upregulating histone deacetylase 5 (HDAC5) through a HIF1α-dependent transcriptional mechanism, thereby promoting de-lactylation of MRE11 and sensitizing cells to radiotherapy. The identification of the HIF1α/HDAC5/MRE11 axis as a critical regulator of radioresistance represents a significant advancement in understanding the intersection of cancer metabolism and DNA repair.

Methods and Experimental Design Insights

The research employed a comprehensive set of molecular and cellular approaches to dissect the interplay between metabolic byproducts and DNA repair mechanisms. Key methodologies included:

• Treatment of TNBC cell lines with exogenous lactate or the glycolytic inhibitor oxamate to modulate cellular lactate levels and examine effects on DNA damage response following irradiation.
• Lentiviral-mediated overexpression and knockdown of MRE11 and HDAC5 to dissect their specific roles in radioresistance and post-translational modification status.
• Western blotting and co-immunoprecipitation (Co-IP) to assess protein-protein interactions and quantify MRE11 lactylation at Lys673.
• Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) and luciferase reporter assays to map HIF1α binding to the HDAC5 promoter and confirm transcriptional regulation.
• Integration of The Cancer Genome Atlas (TCGA) datasets and clinical tissue microarrays to validate HDAC5 expression patterns in patient samples.
• Proteomics-mass spectrometry and gene expression profiling to characterize SSD’s impact on the global proteome and transcriptome in the context of radiotherapy.

To directly link metabolic flux with DNA repair, the authors leveraged both lactate supplementation and the competitive LDH-A inhibitor oxamate—structurally analogous to oxamic acid—as tool compounds for modulating glycolytic activity and lactate production.

Core Findings and Why They Matter

Several mechanistic insights emerged from the study:

• Lactate-Mediated MRE11 Lactylation: Elevated lactate in radioresistant TNBC cells increased MRE11 Lys673 lactylation, enhancing DNA repair efficiency and conferring resistance to irradiation.
• HDAC5 as the Key Delactylase: HDAC5 was identified as the primary enzyme responsible for removing the lactyl group from MRE11 Lys673. Overexpression of HDAC5 reduced MRE11 lactylation and impaired DNA repair, while HDAC5 downregulation correlated with increased resistance.
• SSD Induces HDAC5 via HIF1α: SSD promoted the transcriptional activation of HDAC5 by upregulating HIF1α, which binds to the HDAC5 promoter and increases its expression. This upregulation led to reduced MRE11 lactylation and enhanced radiosensitivity.
• Clinical Validation: Analysis of TCGA data and tissue microarrays demonstrated that HDAC5 expression is frequently reduced in TNBC tumors, supporting its relevance as a therapeutic target.

Together, these results reveal a previously unappreciated mechanism by which glycolytic metabolism and its byproducts directly modulate DNA repair through post-translational modification of repair factors. By reversing this process, SSD and potentially other metabolic reprogramming inhibitors offer a rational strategy to overcome radioresistance in aggressive cancers.

Comparison with Existing Internal Articles

Several internal articles provide complementary context and practical insights for researchers interested in targeting cancer metabolism and radioresistance. For example, "Sodium Oxamate: Targeting Tumor Bioenergetics and Resistance" discusses the use of Sodium Oxamate—a competitive LDH-A inhibitor and oxamic acid analog—to dissect metabolic reprogramming and its role in therapy resistance. The reference study builds directly on this approach, using oxamate to modulate lactate production and thereby probe the functional link between glycolytic flux and MRE11 lactylation in TNBC cells.

Further, "Sodium Oxamate in Cancer Metabolism: Protocols, Insights, and Troubleshooting" provides actionable protocols for using Sodium Oxamate in models of radioresistant TNBC, closely paralleling the reference study’s experimental design. These internal resources reinforce the translational value of targeting the Warburg effect and support adoption of similar glycolytic flux inhibitors in future research.

Limitations and Transferability

While the study provides compelling evidence linking lactate metabolism, MRE11 lactylation, and radioresistance, several limitations merit attention. Most mechanistic insights were derived from in vitro TNBC cell line models, and although supported by clinical data, further validation in patient-derived xenografts or clinical trials is necessary to confirm translatability. The specificity of SSD’s effect on the HIF1α/HDAC5 axis also remains to be fully characterized, as does its safety profile in vivo. Finally, while oxamate and other LDH-A inhibitors are well-established research tools, their direct clinical application as radiosensitizers awaits further pharmacological and toxicological evaluation.

Protocol Parameters

• Oxamate treatment: Dose ranges from low micromolar to millimolar concentrations depending on cell type and experimental design; titrate based on lactate suppression and cytotoxicity as evidenced in the reference study and product information.
• Lactate supplementation: Apply exogenous lactate at physiologically relevant concentrations (e.g., 10-20 mM) to simulate tumor microenvironment conditions that drive lactylation.
• SSD treatment: Use optimized dosing as described in the reference study to evaluate radiosensitization effects.
• HDAC5/MRE11 manipulation: Use lentiviral vectors for overexpression or shRNA-mediated knockdown as required to validate pathway involvement.
• Radiation exposure: Deliver ionizing radiation at clinically relevant doses (e.g., 2-8 Gy) to assess DNA repair outcomes in treated cell populations.

Researchers are encouraged to optimize these parameters for their specific cell models and experimental endpoints, using published protocols as a starting point.

Research Support Resources

For investigators seeking to replicate or extend these findings, Sodium Oxamate (SKU C3893) from APExBIO is a widely used glycolytic flux inhibitor and LDH-A antagonist, suitable for probing the metabolic regulation of DNA repair and therapy resistance. Its utility in cancer metabolism research and tumor bioenergetics study is well-supported both by the reference study and internal research guides. For detailed protocols and troubleshooting in TNBC or related models, see "Sodium Oxamate: Targeting Tumor Bioenergetics and Resistance."